J.Jpn. Surg. Soc.
ISSN 1880-1129

[Abstract] [Full Text PDF] （in Japanese / 2484KB） [Members Only And Two Factor Auth.]

J.Jpn. Surg. Soc.. 92(9): 1212-1216, 1991

Report on the annual meeting

EIGHTEEN-YEAR EXPERIENCE OF CANCER IMMUNOTHERAPIES
―EVALUATION OF THEIR THERAPEUTIC BENEFITS AND FUTURE―

1) The First Department of Surgery, Kyushu University School of Medicine, Fukuoka, Japan
2) Department of Surgery, Saga Medical School, Saga, Japan
3) Kimura Surgical Hospital, Fukuoka, Japan

Motomichi Torisu1), Akihiko Uchiyama1), Tomomochi Goya1), Kazunori Iwasaki1), Mitsuo Katano2), Hiroshi Yamamoto2), Yutaka Kimura3)

The purpose of this study is to evaluate the therapeutic benefits of cancer immunotherapies and to predict the future of these therapies. The results of our clinical trials are as follows ; (1) A group of gastric and colonic cancer patients at stages III-IV treated with BCG immunotherapy showed a significant prlongation of survival period. (2) A significant prolongation of the disease-free period and the survival time were observed in the PSK-treated group in a randomized clinical trial on patients with curative surgical operation for stages III-IV colonic cancer. (3) We established clinically that intracavital administration of OK-432 is a useful therapy for patients with malignant pleuro-peritoneal effusions. We found that the reduction and disappearance of effusions were observed in more than 60% of patients with this therapy and they survived significantly longer. These results indicate that the immunotherapies may be effective to prolong survival period of advanced cancer patients with improvement of their quality of life. Furthermore, a series of our studies on the intracavital OK-432 injections for malignant ascites are useful to understand the reaction of host immune system against tumor cells.

<< To previous pageTo next page >>

To read the PDF file you will need Adobe Reader installed on your computer.